Oncgnostics develops IVD tests for screening, therapeutic decision making, and follow-up care in cancer diagnostics.
oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable in vitro diagnostic (=IVD) tests for screening, therapeutic decisions and follow-up care in cancer diagnostics.The diagnostic tests developed by oncgnostics are based on DNA regions specifically methylated in precancerous and carcinoma cells. These marker regions are detected using well-established PCR-based technologies, which can be performed in routine molecular diagnostics laboratories with standard equipment. oncgnostics has identified novel markers for detecting cervical precancerous lesions and carcinomas.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 29, 2015 | Series A | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sparkasse Jena | — | Series A |